Featured Platforms

Custom Protein Generation

Mammalian- Derived Products

Microbial- Derived Products

Antibody Drug Conjugates

Bispecific Ab Platform

Technologies & Platforms

Corporate Profile        中文

WUXI BIOLOGICS (CAYMAN) INC. (“WUXI BIOLOGICS” or the “Company”), is a global leading biologics services provider that offers comprehensive, integrated and highly customizable services through its teams of scientists, proprietary technology platform and know-how, state-of-the-art laboratories, and cGMP-compliant manufacturing facilities to pharmaceutical and biotechnology companies.

The company is a leading global open-access biologics technology platform in the world offering end-to-end solutions, empowering anyone to discover, develop and manufacture biologics from concept to commercial manufacturing. Its business model is built upon a strategy of following the molecule, whereby customers’ demand for the company’s services increases as their biologics advance through development and ultimately to commercialization, which allows its revenue from each integrated project to grow as the project advances.

Headquartered in Wuxi, Jiangsu, China with three operation sites located in Wuxi, Shanghai and Suzhou, respectively, WuXi Biologics is the dominant leader in China’s biologics services market with 63.5% market share in terms of revenue in 2017 and also held leading market positions globally. To date, the company has worked with 13 out of the 20 largest pharmaceuticals companies in the world, including renowned industry players such as AstraZeneca and Genentech.

WuXi Biologics: Transforming and accelerating pharmaceutical discovery, development and manufacturing in the fast growing field of biologics to benefit patients worldwide.